EMA Multinational Assessment Teams Move Into Post-Authorization After Delay
Executive Summary
The scope of the European Medicines Agency’s multinational assessment team initiative was originally due to expand in April from the pre-authorization to the post-authorization phase. It will happen next month instead.
You may also be interested in...
EU Widens Use Of Multinational Assessment Teams As Demand Rises
Regulatory procedures involving several national agencies are likely to increase after the European Medicines Agency extended the use of multinational assessment teams in the post-authorization phase.
EU Regulator Raises Possibility Of Shorter Drug Approval Timelines
With the EU pharmaceutical legislation due to undergo a radical shake-up to create a future-proof regulatory system, the time is ripe for industry to engage with efforts to make the European drug approval process more agile.
EMA’s Multinational Approach Brings All But Two Member States Into New Drug Assessor Fold
The multinational assessment team (MNAT) approach aimed to involve more EU member states in the evaluation of new medicines. EMA views it as a success, although only about 10% of marketing authorization applications submitted for initial evaluation in 2015 involved MNATs. It will shortly be expanded to certain post-authorization procedures and is being promoted as a tool that will help the agency deal with Brexit fallout.